Narration (00:04) Welcome to 340B Insight from 340B Health. David Glendinning (00:13) Hello from Washington, D.C., and welcome back to 340B Insight, the premier podcast about the 340B drug pricing program. I'm your host, David Glendinning with 340B Health. The federal government's plans to impose a new 340B rebate system starting January 1st are raising major concerns for hospitals across the country. This program would fundamentally change how hospitals receive 340B savings on certain outpatient drugs. Creating new financial pressures and administrative burdens. But significant efforts are underway to try to stop the program before it takes effect. I recently discussed these developments with our very own Amanda Nagrotsky on our legal and policy team. Amanda walked us through the latest details of the rebate program, the legal and legislative efforts to stop it, and what hospitals should be doing to prepare for January 1st. Here's that conversation. I am speaking with 340B Health Vice President of Legal and Policy, Amanda Nagrotsky. Amanda, welcome back to 340B Insight. It's great to have you with us again. Amanda Nagrotsky (01:20) Thanks very much, David. Happy to be here. David Glendinning (01:22) Amanda, we've spoken about the rebate issue on this podcast before, but a lot has happened in recent weeks. Before we get into the latest developments, let's just remind listeners a little bit how this rebate model in general would work and how it differs from the 340B program hospitals have relied on for decades. Amanda Nagrotsky (01:46) Manufacturers have traditionally met their 340B pricing obligations through upfront discounts. And rather than receiving discounts that are built into purchase prices of medications, the rebate model allows manufacturers to require hospitals to pay significantly higher upfront prices for 340B drugs, submit documentation, and then wait for rebates that reflect the difference between. the higher list price and the 340B price. So by delaying access to upfront discounts, the rebate program would require hospitals to effectively front or float that cost difference to drug companies. And this can create cash flow challenges for 340B hospitals, having to pay that higher list price up front and then wait for rebates. And The rebate program would require hospitals to submit rebate claims, track and reconcile payments, and address rebate delays and denials. These are all new administrative burdens and costs that don't exist with upfront discounts. 340B Health is strongly opposed to 340B rebates. David Glendinning (03:04) And now, for better or worse, we have a much clearer picture of what these types of rebates will look like in practice. HRSA or the uh Health Resources and Services Administration recently announced which drug companies and drugs will be included in the rebate program starting uh early next year. So what did we learn from that announcement and were there any surprises when it came out? Amanda Nagrotsky (03:31) HRSA recently approved drug company 340B rebate plans for 18 drugs beginning January 1, 2027. These are drugs that are subject to Medicare negotiated pricing in 2026 or 2027, but rebates would apply across all payers and uses of these drugs. The drugs are commonly used drugs for diabetes, cardiovascular disease, cancer, and other conditions. All 10 companies approve for rebates are using Beacon as their rebate vendor. And drug companies are required to pay rebates within 10 days after covered entities submit complete rebate claims. Some major drugs were not on the approved list from HRSA. Novo Nordisk's GLP1 and AstraZeneca's Calcleans are not Going to be subject to rebates starting in January because the manufacturers chose not to apply for rebates for those drugs. And the manufacturers didn't say why. Uh, but you know, there's been speculation in the press that Novo Nordis didn't want to put its products at a disadvantage compared to other GLP1 drugs that it's in competition with. And there's similar speculation for AtraZeneca. Who didn't submit a plan for Calcleans. It's a drug that's used to treat blood cancers. And Abvi's Imbruvica is its main competitor. And Imbruvica was approved for rebates. So this is potentially a way for AstraZeneca to distinguish its drug. David Glendinning (05:15) Okay, so a little bit of intrigue there. You mentioned earlier the additional costs and administrative burdens that will come with this rebate model. Let's dig a little deeper into that. What could this new system mean for hospital finances and their day-to-day operations? Amanda Nagrotsky (05:37) You know, I think a key takeaway is that for the drugs that are subject to rebates, manufacturers would have much more control of 340 B than they otherwise would. You know, HRSA did place additional limits on manufacturers' ability to deny rebates compared to last year. In addition to prohibiting denials on diversion and duplicate discount grounds, manufacturers can't deny claims based on eligibility concerns or a perceived That's in quotes perceived lack of whack purchases. HRSA says manufacturers can raise those concerns with covered entities or uh with HRSA. And it's not clear whether HRSA will permit denials based on drug company evidence of a whack purchase or whether, you know, any and all rebate discrepancies are just perceived, which would require the manufacturer, at least under HERSA's Notice to discuss that with the covered entity in HRSA or you know, pursue audits rather than denying a rebate. But the sort of prospect for rebate delays and denials are, I think, a really important piece. If manufacturers deny rebates, hospitals then need to chase down payments. and if they don't get the rebates, they would need to resort to filing. A claim under Hearse's administrative dispute resolution process, the ADR process, which is, you know, relatively new and untested. And again, you know, hospitals will have to pay higher upfront prices for affected drugs, which could create potential cash flow challenges and put 340B savings at risk if drug companies delay or deny rebates. And this is on top of new administrative costs. And burdens that stem from you know these rebate-related tasks that again don't exist under an upfront discount program. 340B hospitals are entering 2027 already facing significant financial pressures as patients are coming off of Medicaid roles in response to incentives under the HR1 legislation. 340B hospitals are going to be subsidizing even more. Healthcare services for low-income patients and will be caring for newly uninsured individuals. And the rebate program is going to reduce the resources that 340B hospitals have for this care. There's also Medicare drug reimbursement cuts under the Inflation Reduction Act that 340B hospitals are contending with. And for many 340B hospitals, significant cuts to Medicare Part B reimbursement for 340B drugs. The rebate program obviously will make it more challenging for 340B hospitals that are already facing significant financial pressures. David Glendinning (08:34) course this isn't the first time Hursa has tried to move forward with a rebate model. The agency had a previous plan that was uh supposed to take effect at the beginning of this year but never did. Remind us what happened with that first attempt and how we got to where we are today. Amanda Nagrotsky (08:51) Yeah, it's a little bit of deja vu in a way. But HRSA had finalized a rebate program for 10 drugs to take effect on January 1, 2026. And late last year, the American Hospital Association led a lawsuit to block HRSA from implementing that rebate program. And that lawsuit was successful. Just before the start of the new year, a federal court in Maine had issued a ruling that temporarily blocked HRSA from moving forward with the rebate program. And then HRSA later completely withdrew the rebate program. But shortly after that happened, HRSA issued a new uh uh issued a request for information on a new rebate program for 2027. HRSA moved forward and issued a final rebate notice in July. David Glendinning (09:43) And that history brings us to the latest legal challenge. Uh we know hospital associations, some of their members have gone back to federal court seeking to stop this new version of the rebate program. So what are their main arguments in this lawsuit? And what exactly are they asking the court to do? Amanda Nagrotsky (10:01) The AHA, the Maine Hospital Association, and four hospitals filed this lawsuit on October 9th. They filed in the U.S. District Court for the District of Maine, which is the same court that blocked Hearse's previous attempt to implement a rebate program. The plaintiffs are asking the court to issue an immediate temporary restraining order stopping the new rebate program while the litigation proceeds and ultimately. uh to block the program from taking effect. The hospitals argue that HRSA failed to adequately assess the costs and administrative burdens that a rebate program would impose. And the lawsuit also claims that HRSA has really overstated the benefits of a rebate program. One of the sort of purported benefits that HRSA, you know, talks about in the rebate notice is the idea that, you know, rebates would resolve Duplicate discounts. The hospitals in the lawsuit argue that HRSA effectively, you know, rubber stamped what the drug company said about duplicate discounts and the benefit of a rebate model without really evaluating those statements and just taking them at face value. David Glendinning (11:16) Those who read our newsletters and alerts know that 340 B Health is playing a role in this litigation as well through a brief supporting the hospitals. What are we telling the court in this case? And I'll also ask on the other side of the case, several drug companies have gotten involved in defending the rebate program. Um, so maybe you could speak about their role as well. Amanda Nagrotsky (11:39) 340B Help did file an amicus brief in this lawsuit in support of the hospital plaintiffs. We filed this brief with America's Essential Hospitals, the Association of American Medical Colleges, and the Children's Hospital Association. And our brief focuses on just how devastating a rebate program would be, could for 340B hospitals. So our brief. Asserts that Hearsa didn't adequately assess the costs and administrative burdens of a rebate program on hospitals, supporting, you know, what the hospital plaintiffs argue in their brief. And we noted that statements in Hearsa's explanation for why it was not increasing the estimate of the burden of the rebate program on providers are virtually identical to assertions that. Almost all of the drug companies uh made in their comments that they submitted to HURSA on the rebate program. So our brief points out that, you know, those comments from hospitals show that virtually all of them said that rebate reporting would not be easy and that managing the rebate process would impose significant costs and again have consequences for hospitals and the services that they provide. You know, manufacturers have claimed that. 340B MCO claims are a significant source of uh Medicaid duplicate discounts. But we point out in our brief that under federal law, responsibility for preventing duplicate discounts on 340B drugs dispensed to Medicaid MCO beneficiaries falls with state Medicaid agencies. You mentioned, David, that uh a couple of manufacturers and pharma have moved to intervene and they recently were. granted permission to intervene in AHA's rebate lawsuit. So this will allow them to defend, you know, their rebate program directly as as parties now to this case. And in making the case to the court for why they should be permitted to intervene, you know, one of their arguments was that the government wouldn't be expected to adequately represent the financial interests of these drug companies. David Glendinning (13:59) So clearly there's a major legal battle underway, uh, but we also know that's not the only effort to stop these rebates. There's also a new uh piece of legislation in the House of Representatives. Tell us about that bill and what it would do. Amanda Nagrotsky (14:15) Yeah, so this is legislation uh that was recently introduced by House Representatives uh Breznahan, Dingle, Mann, and Frankel of Pennsylvania, Michigan, Kansas, and Florida, uh, respectively. So it's the 340B Rebate Model Delay Act, which would delay implementation of the rebate program by two years through 2028. And 340B Health is supporting efforts to advance this legislation and working to have it included in year end legislation. And we also continue to advocate that Senate appropriators include language to prohibit federal front funds from being used to implement uh the rebate program in their final appropriations legislation. David Glendinning (15:05) So we've talked about all of these efforts to stop this rebate program. Some of our listeners might be wondering whether they can hold off on preparing for rebates, at least while the the lawsuit plays out and we see what happens on on Capitol Hill. What would your advice be to hospitals in general about what they should be doing right now? Amanda Nagrotsky (15:26) Yeah, I understand, you know, why hospitals would be wondering that. But I would say, you know, it's important to be prepared. There are no guarantees, whether it be with, you know, the legal efforts or or legislative efforts. I think it is just wiser and safer to to be prepared for the rebate program to be implemented on January one. That could be, you know, its own podcast. But one of the things that I think is really important. Is of course being familiar with the manufacturer plans that have been approved, that the drugs that rebates have been approved for, and you know, having a sense of what your purchasing history is, you know, for those drugs. Thinking about if you're gonna have to buy these drugs at WAC and submit claims data and then wait for rebates from a cash flow perspective, what does that mean for your organization? Having a plan for submitting, you know, the data. So Manufacturers, you know, have to pay the rebates within 10 days of completed rebate submissions. So that's when you know that clock starts ticking. So being able, being prepared to submit the data is really important. And then having, you know, processes outlined for not only claim submission, but tracking and reconciling payments and then being prepared. as best you can be, I suppose, for you know, potential rebate delays and denials. Also important, I think, to have a plan for if you find yourself in a situation where you're seeing, you know, delays or denials, so important to communicate that, report that really to HRSA. Coordinating there are just multiple departments that are going to be involved with this undertaking. Obviously pharmacy You know, and compliance, but finance and IT, you know, with the the claim status submission piece, it's really important, I think, to, you know, make sure that you're communicating with the folks, the departments in your hospital that are all going to be working on this. Collaborating with your TPAs as well is another uh important piece. David Glendinning (17:44) We're just now a couple months away from, as you mentioned, the planned start of the rebate program. Still a great deal that could happen between now and then. But in the meantime, what should our listeners be watching for over the next several weeks? And um how can hospitals be helping you, helping all of us here at three hundred forty B Health in our in our efforts to stop this program? Amanda Nagrotsky (18:06) 40B Health is a resource. We have resources on our website about the rebate program, and we'll be providing additional resources related to rebate implementation. So that is something to certainly keep watch for. You know, in terms of how hospitals can help with sort of the legislative efforts, something that's really important is if your hospital does not think that it will be ready to submit. data or otherwise implement the rebate program on January one, we would strongly encourage hospitals to to share that information with us. It's it's really important. David Glendinning (18:45) We will put as many of those resources we have for now for our members in the show notes as we can. Uh, Amanda, I feel like our newsletters and alerts lately have been like the 340B law review. So I very much appreciate you being here to help us get those out to our members and to get these types of discussions out to all our listeners. Thank you again for being here. Amanda Nagrotsky (19:08) Thanks so much for having me, David. David Glendinning (19:10) Thanks again to Amanda Nogratsky for joining us to discuss the latest developments surrounding the 340B rebate program. As she mentioned, the coming weeks will be critical as the courts consider whether to block the program and Congress weighs legislation to put it on hold. In the meantime, hospitals should continue preparing for the possibility that rebates will take effect on January 1st. We encourage our 340B health members to follow our ongoing coverage. and share with us how the rebate program could affect your operations and the patients you serve. We will be back in a few weeks with our next episode. In the meantime, as always, thanks for listening and be well. Narration (19:55) Thanks for listening to 340B Insight. Subscribe and rate us on Apple Podcasts, Google Play, Spotify, or wherever you listen to podcasts. For more information, visit our website at 340bpodcast.org. You can also follow us on Twitter at 340b Health and submit a question or idea to the show by emailing us at podcast at 340bhealth.org.